Assertio (ASRT) Competitors $0.82 +0.03 (+3.75%) As of 10:08 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ASRT vs. DSGN, GLUE, OCGN, RNAC, AVIR, NGNE, LFCR, ACB, CTNM, and VORShould you be buying Assertio stock or one of its competitors? The main competitors of Assertio include Design Therapeutics (DSGN), Monte Rosa Therapeutics (GLUE), Ocugen (OCGN), Cartesian Therapeutics (RNAC), Atea Pharmaceuticals (AVIR), Neurogene (NGNE), Lifecore Biomedical (LFCR), Aurora Cannabis (ACB), Contineum Therapeutics (CTNM), and Vor Biopharma (VOR). These companies are all part of the "pharmaceutical products" industry. Assertio vs. Its Competitors Design Therapeutics Monte Rosa Therapeutics Ocugen Cartesian Therapeutics Atea Pharmaceuticals Neurogene Lifecore Biomedical Aurora Cannabis Contineum Therapeutics Vor Biopharma Design Therapeutics (NASDAQ:DSGN) and Assertio (NASDAQ:ASRT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, media sentiment, valuation, dividends and profitability. Which has more volatility and risk, DSGN or ASRT? Design Therapeutics has a beta of 1.61, suggesting that its stock price is 61% more volatile than the S&P 500. Comparatively, Assertio has a beta of 0.35, suggesting that its stock price is 65% less volatile than the S&P 500. Do analysts rate DSGN or ASRT? Assertio has a consensus price target of $2.38, suggesting a potential upside of 188.23%. Given Assertio's stronger consensus rating and higher probable upside, analysts clearly believe Assertio is more favorable than Design Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Design Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Assertio 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Which has stronger earnings and valuation, DSGN or ASRT? Assertio has higher revenue and earnings than Design Therapeutics. Design Therapeutics is trading at a lower price-to-earnings ratio than Assertio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDesign TherapeuticsN/AN/A-$49.59M-$1.12-5.20Assertio$124.96M0.63-$21.58M-$0.45-1.83 Is DSGN or ASRT more profitable? Design Therapeutics has a net margin of 0.00% compared to Assertio's net margin of -36.97%. Design Therapeutics' return on equity of -27.15% beat Assertio's return on equity.Company Net Margins Return on Equity Return on Assets Design TherapeuticsN/A -27.15% -26.07% Assertio -36.97%-38.19%-15.45% Do insiders & institutionals believe in DSGN or ASRT? 56.6% of Design Therapeutics shares are held by institutional investors. Comparatively, 49.0% of Assertio shares are held by institutional investors. 23.5% of Design Therapeutics shares are held by company insiders. Comparatively, 4.0% of Assertio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the media refer more to DSGN or ASRT? In the previous week, Design Therapeutics and Design Therapeutics both had 2 articles in the media. Design Therapeutics' average media sentiment score of 1.33 beat Assertio's score of 0.08 indicating that Design Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Design Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Assertio 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryAssertio beats Design Therapeutics on 8 of the 14 factors compared between the two stocks. Get Assertio News Delivered to You Automatically Sign up to receive the latest news and ratings for ASRT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ASRT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ASRT vs. The Competition Export to ExcelMetricAssertioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$79.21M$2.84B$5.76B$9.82BDividend YieldN/A48.51%6.66%4.48%P/E Ratio-1.8322.8583.0526.53Price / Sales0.63720.08528.17110.27Price / Cash17.0126.3325.7028.92Price / Book0.856.9111.026.61Net Income-$21.58M$32.94M$3.28B$265.84M7 Day Performance7.01%1.12%0.42%-0.09%1 Month Performance15.65%8.56%10.90%6.78%1 Year Performance-25.77%0.80%53.91%22.77% Assertio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ASRTAssertio2.0977 of 5 stars$0.82+3.8%$2.38+188.2%-32.7%$79.21M$124.96M-1.8320DSGNDesign Therapeutics0.2925 of 5 stars$5.20-1.1%N/A+20.6%$299.55MN/A-4.6440News CoveragePositive NewsGLUEMonte Rosa Therapeutics2.7376 of 5 stars$4.59-4.8%$15.33+234.1%-20.3%$297.68M$75.62M12.7590News CoveragePositive NewsOCGNOcugen1.2426 of 5 stars$1.04+3.0%$6.00+476.9%-20.8%$295.23M$4.75M-5.2080News CoverageRNACCartesian Therapeutics2.2122 of 5 stars$11.25+0.2%$40.00+255.6%-29.5%$292M$38.91M-0.2164News CoveragePositive NewsAVIRAtea Pharmaceuticals2.4116 of 5 stars$3.66flat$6.00+63.9%-11.7%$290.45MN/A-2.2770News CoverageNGNENeurogene1.7118 of 5 stars$19.98-0.1%$46.17+131.1%-47.5%$285.30M$930K-4.6490News CoveragePositive NewsLFCRLifecore Biomedical0.7508 of 5 stars$7.59-0.1%$8.00+5.4%+70.3%$284.30M$128.87M-5.79690Positive NewsACBAurora Cannabis0.2672 of 5 stars$5.23+4.8%N/A-15.0%$281.70M$246.72M-27.531,130Gap DownCTNMContineum Therapeutics2.6902 of 5 stars$10.39+4.5%$22.75+119.0%-42.7%$278.74M$50M-4.7231Short Interest ↑VORVor Biopharma0.5354 of 5 stars$2.06-5.1%N/AN/A$274.90MN/A-0.15140Positive NewsGap Up Related Companies and Tools Related Companies Design Therapeutics Competitors Monte Rosa Therapeutics Competitors Ocugen Competitors Cartesian Therapeutics Competitors Atea Pharmaceuticals Competitors Neurogene Competitors Lifecore Biomedical Competitors Aurora Cannabis Competitors Contineum Therapeutics Competitors Vor Biopharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ASRT) was last updated on 9/3/2025 by MarketBeat.com Staff From Our PartnersHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe $365M annual revenue crypto play While Bitcoin generates zero operational revenue, one DeFi protocol qu...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Assertio Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Assertio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ASRT Stock Alerts